Search

Recursion Pharmaceuticals Inc

Closed

SectorHealthcare

3.54 -6.84

Overview

Share price change

24h

Current

Min

3.4699999999999998

Max

3.86

Key metrics

By Trading Economics

Income

12M

-119M

Sales

11M

19M

EPS

-0.22

Profit margin

-641.634

Employees

600

EBITDA

-11M

-123M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+88.45% upside

Market Stats

By TradingEconomics

Market Cap

252M

2.3B

Previous open

10.38

Previous close

3.54

Recursion Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

6 Nov 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. is trading higher in after-market hours, reaching its highest level since Friday's close.

5 Nov 2026, 23:22 UTC

Correlated Moves

Recursion Pharmaceuticals, Inc. is trading lower in after-market hours, in line with a broader market decline and losses in the ARK Genomic Revolution ETF (ARKG).

4 Nov 2026, 21:04 UTC

Correlated Moves

Recursion Pharmaceuticals shares are rising during Wednesday's session, following a broader biotechnology sector increase and strong gains in the SPDR S&P Biotech ETF.

3 Nov 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. is moving higher in after-market hours, reflecting broader market gains amid strong economic data influencing Federal Reserve policy.

2 Nov 2026, 23:02 UTC

Social Media
News

Recursion Pharmaceuticals appointed Fred Hassan as Chair of the Board, effective October 31, 2026, and reported positive Phase 2 data for REC-4881.

31 Oct 2026, 00:01 UTC

Recursion Pharmaceuticals, Inc. is trading lower in after-market hours, having declined from Friday's close amid volatility and stabilization near its one-month range.

30 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. declined during after-market hours, with cumulative returns falling since Friday's close after briefly peaking earlier in the session.

29 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. shares declined during after-market hours on Thursday, breaking a trend of higher daily closes established earlier in the week.

28 Oct 2026, 23:02 UTC

Recursion Pharmaceuticals, Inc. is trading lower in after-market hours, reflecting the broader market's decline and retracing from an earlier session high.

27 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals, Inc. is declining in after-market hours, marking a significant retracement from recent highs after finishing higher for three consecutive sessions.

26 Oct 2026, 20:07 UTC

Recursion Pharmaceuticals Inc shares are advancing, having reached an early peak but ultimately settling lower near the lower end of their one-month range.

24 Oct 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares are trading lower in after-market hours, having retraced from a brief peak earlier in the session.

23 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

22 Oct 2026, 23:02 UTC

Recursion Pharmaceuticals Inc is experiencing a significant decline in after-market trading, moving lower since Thursday's close and reaching its lowest point of the day.

21 Oct 2026, 23:51 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading lower in after-market hours, reflecting broader market trends and positioning below its 20-day moving average.

20 Oct 2026, 23:02 UTC

Social Media

Recursion Pharmaceuticals Inc shares are trading modestly lower in after-market hours, with approximately $561 million in cash at the end of the quarter.

19 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is advancing in after-market trading, maintaining an upward trajectory since Monday's close.

17 Oct 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares advanced modestly higher during after-market hours on Friday, diverging from the recent trend of higher daily closes.

16 Oct 2026, 23:06 UTC

Recursion Pharmaceuticals Inc shares are modestly higher in after-market trading.

15 Oct 2026, 20:03 UTC

News
Event
Macro Event

Recursion Pharmaceuticals announces a $200 million oversubscribed follow-on offering and positive updates on drug candidate REC-4881, achieving a 47% median reduction in polyp burden.

14 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, aligning with broader market losses amid rising inflation concerns and geopolitical tensions affecting oil supply.

13 Oct 2026, 23:06 UTC

Recursion Pharmaceuticals Inc is trading modestly higher in after-market hours following Tuesday's close.

12 Oct 2026, 20:02 UTC

Recursion Pharmaceuticals Inc shares are sharply lower, continuing a downward trend since Friday, despite an early spike in today's trading session.

10 Oct 2026, 00:01 UTC

Recursion Pharmaceuticals Inc shares advanced during after-market hours on Friday, despite earlier pulling back from a session high.

9 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is trading modestly higher in after-market hours, recovering from an earlier decline while remaining well above its 20-day moving average.

8 Oct 2026, 20:01 UTC

News
Correlated Moves

Recursion Pharmaceuticals faces downward pressure amid significant insider transactions, including a 50k share sale by Director Borgeson Blake on October 6.

7 Oct 2026, 23:05 UTC

Recursion Pharmaceuticals Inc is trading lower in after-market hours, continuing a trend of three consecutive sessions finishing lower since Wednesday's close.

6 Oct 2026, 20:02 UTC

Correlated Moves
Social Media
News

Recursion Pharmaceuticals Inc. shares fell amid sector declines, with attention on upcoming Phase 2 data for REC-4881 and ongoing trials for other candidates.

5 Oct 2026, 23:01 UTC

Recursion Pharmaceuticals Inc is declining in after-market trading, continuing lower since Monday's close, despite remaining above its 20-day moving average.

2 Oct 2026, 20:07 UTC

Correlated Moves

Recursion Pharmaceuticals Inc is trading higher, supported by a favorable market environment and positive sentiment following recent labor statistics.

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

88.45% upside

12 Months Forecast

Average 6.633 USD  88.45%

High 8 USD

Low 5.9 USD

Based on 4 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

4 ratings

2

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
help-icon Live chat